This proposal has three parts: 1) a study of the epidemiology of AIDS in I.V. drug abusers, 2) a study of neuropsychological and personality function in HIV seropositive I.V. drug abusers, and 3) a study of their social networks aimed at obtaining data that may be used to develop interventions to reduce high risk behavior. The first study will evaluate the prevalence of seropositivity among a cohort of I.V. drug abusers both in and out of treatment in the Philadelphia area. It will obtain data allowing the assessment of the rates at which seronegatives become positive among subjects in both groups, and on the behaviors that are associated with this change. It will also provide data on the rate of disease progression is more common in individuals with certain demographic characteristics such as age, race, sex or treatment status. The second study will assess the epidemiology of neuropsychological dysfunction in HIV seropositive users, will characterize this dysfunction, will relate neuropsychological functioning to medical status, and will create a database to address future research questions in this area. The third study will obtain information about the social networks of I.V. drug abusers both in and out of treatment. Subjects selected for this study will be chosen from a cohort of those in the epidemiological study. This study will aim to define the social support networks of I.V. drug abusers to determine points of influence which may be useful in developing intervention programs that can alter and sustain change in high risk behavior. This study will fill a void in research on AIDS in intravenous drug abuse both generally and in the Philadelphia area. It will also provide a new and exciting initiative for our ongoing drug abuse research program, and will be coordinated through our Center for Research on the Treatment and Prevention of Intravenous Drug Abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA005593-03
Application #
3212057
Study Section
Sociobehavioral Subcommittee (DAAR)
Project Start
1989-03-01
Project End
1992-06-30
Budget Start
1991-03-01
Budget End
1992-06-30
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fureman, I; Meyers, K; McLellan, A T et al. (1997) Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials. AIDS Educ Prev 9:330-41
Davis, R F; Metzger, D S; Meyers, K et al. (1995) Long-term changes in psychological symptomatology associated with HIV serostatus among male injecting drug users. AIDS 9:73-9
Meyers, K; Metzger, D S; McLellan, A T et al. (1995) Will preventive HIV vaccine efficacy trials be possible with female injection drug users? J Acquir Immune Defic Syndr Hum Retrovirol 10:577-85
Meyers, K; Metzger, D S; Navaline, H et al. (1994) HIV vaccine trials: will intravenous drug users enroll? Am J Public Health 84:761-6
Cohen, E; Navaline, H; Metzger, D (1994) High-risk behaviors for HIV: a comparison between crack-abusing and opioid-abusing African-American women. J Psychoactive Drugs 26:233-41
Zanis, D A; Metzger, D S; McLellan, A T (1994) Factors associated with employment among methadone patients. J Subst Abuse Treat 11:443-7
Frank, I; Fishman, N (1994) Epidemiology and clinical manifestations of human immunodeficiency virus infection. Semin Roentgenol 29:230-41
Metzger, D S; Woody, G E; McLellan, A T et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6:1049-56
Watkins, K E; Metzger, D; Woody, G et al. (1993) Determinants of condom use among intravenous drug users. AIDS 7:719-23
DePhilippis, D; Metzger, D S; Woody, G E et al. (1992) Attitudes toward mandatory human immunodeficiency virus testing and contact tracing. A survey of intravenous drug users in treatment. J Subst Abuse Treat 9:39-42

Showing the most recent 10 out of 11 publications